{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T21:50:52Z","timestamp":1789854652137,"version":"4.0.1"},"reference-count":122,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,7,10]],"date-time":"2018-07-10T00:00:00Z","timestamp":1531180800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,7,10]],"date-time":"2018-07-10T00:00:00Z","timestamp":1531180800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004396","name":"Thailand Research Fund","doi-asserted-by":"publisher","award":["RTA6080003"],"award-info":[{"award-number":["RTA6080003"]}],"id":[{"id":"10.13039\/501100004396","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004192","name":"National Science and Technology Development Agency","doi-asserted-by":"publisher","award":["Research Chair Grant"],"award-info":[{"award-number":["Research Chair Grant"]}],"id":[{"id":"10.13039\/501100004192","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002842","name":"Chiang Mai University","doi-asserted-by":"publisher","award":["Center of Excellence Award"],"award-info":[{"award-number":["Center of Excellence Award"]}],"id":[{"id":"10.13039\/501100002842","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Diabetes mellitus currently affects over 350\u00a0million patients worldwide and is associated with many deaths from cardiovascular complications. Sodium\u2013glucose co-transporter 2 (SGLT-2) inhibitors are a novel class of antidiabetic drugs with cardiovascular benefits beyond other antidiabetic drugs. In the EMPA-REG OUTCOME trial, empagliflozin significantly decreases the mortality rate from cardiovascular causes [38% relative risk reduction (RRR)], the mortality rate from all-causes (32% RRR) and the rate of heart failure hospitalization (35% RRR) in diabetic patients with established cardiovascular diseases. The possible mechanisms of SGLT-2 inhibitors are proposed to be systemic effects by hemodynamic and metabolic actions. However, the direct mechanisms are not fully understood. In this review, reports concerning the effects of SGLT-2 inhibitors in models of diabetic cardiomyopathy, heart failure and myocardial ischemia from in vitro, in vivo as well as clinical reports are comprehensively summarized and discussed. By current evidences, it may be concluded that the direct effects of SGLT-2 inhibitors are potentially mediated through their ability to reduce cardiac inflammation, oxidative stress, apoptosis, mitochondrial dysfunction and ionic dyshomeostasis.<\/jats:p>","DOI":"10.1186\/s12933-018-0745-5","type":"journal-article","created":{"date-parts":[[2018,7,10]],"date-time":"2018-07-10T10:15:55Z","timestamp":1531217755000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":140,"title":["Potential mechanisms responsible for cardioprotective effects of sodium\u2013glucose co-transporter 2 inhibitors"],"prefix":"10.1186","volume":"17","author":[{"given":"Charshawn","family":"Lahnwong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siriporn C.","family":"Chattipakorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3026-718X","authenticated-orcid":false,"given":"Nipon","family":"Chattipakorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,10]]},"reference":[{"key":"745_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2174\/1573399812666151016101622","volume":"13","author":"M Lotfy","year":"2017","unstructured":"Lotfy M, Adeghate J, Kalasz H, Singh J, Adeghate E. Chronic complications of diabetes mellitus: a mini review. Curr Diab Rev. 2017;13:3\u201310.","journal-title":"Curr Diab Rev"},{"key":"745_CR2","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1056\/NEJMoa0706245","volume":"358","author":"P Gaede","year":"2008","unstructured":"Gaede P, Lund-Andersen H, Parving H-H, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358:580\u201391.","journal-title":"N Engl J Med"},{"key":"745_CR3","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1161\/CIR.0000000000000366","volume":"133","author":"D Mozaffarian","year":"2016","unstructured":"Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Executive summary: heart disease and stroke statistics\u20142016 update: a report from the american heart association. Circulation. 2016;133:447\u201354.","journal-title":"Circulation"},{"key":"745_CR4","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.pharmthera.2014.01.003","volume":"142","author":"K Huynh","year":"2014","unstructured":"Huynh K, Bernardo BC, McMullen JR, Ritchie RH. Diabetic cardiomyopathy: mechanisms and new treatment strategies targeting antioxidant signaling pathways. Pharmacol Ther. 2014;142:375\u2013415.","journal-title":"Pharmacol Ther"},{"key":"745_CR5","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.hfc.2012.06.007","volume":"8","author":"JD Schilling","year":"2012","unstructured":"Schilling JD, Mann DL. Diabetic cardiomyopathy: bench to bedside. Heart Fail Clin. 2012;8:619\u201331.","journal-title":"Heart Fail Clin."},{"key":"745_CR6","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ijcard.2004.03.009","volume":"101","author":"F Gonz\u00e1lez-V\u00edlchez","year":"2005","unstructured":"Gonz\u00e1lez-V\u00edlchez F, Ayuela J, Ares M, Pi J, Castillo L, Mart\u00edn-Dur\u00e1n R. Oxidative stress and fibrosis in incipient myocardial dysfunction in type 2 diabetic patients. Int J Cardiol. 2005;101:53\u20138.","journal-title":"Int J Cardiol"},{"issue":"131","key":"745_CR7","first-page":"897","volume":"2017","author":"M Tate","year":"1979","unstructured":"Tate M, Grieve DJ, Ritchie RH. Are targeted therapies for diabetic cardiomyopathy on the horizon? Clin Sci Lond Engl. 1979;2017(131):897\u2013915.","journal-title":"Clin Sci Lond Engl"},{"key":"745_CR8","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cmet.2017.04.011","volume":"26","author":"E Ferrannini","year":"2017","unstructured":"Ferrannini E. Sodium\u2013glucose co-transporters and their inhibition: clinical physiology. Cell Metab. 2017;26:27\u201338.","journal-title":"Cell Metab"},{"key":"745_CR9","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1007\/s00424-014-1619-7","volume":"467","author":"I Vrhovac","year":"2015","unstructured":"Vrhovac I, Balen Eror D, Klessen D, Burger C, Breljak D, Kraus O, et al. Localizations of Na(+)-d-glucose cotransporters SGLT1 and SGLT2 in human kidney and of SGLT1 in human small intestine, liver, lung, and heart. Pflugers Arch. 2015;467:1881\u201398.","journal-title":"Pflugers Arch"},{"key":"745_CR10","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s11897-017-0340-1","volume":"14","author":"FH Verbrugge","year":"2017","unstructured":"Verbrugge FH. Role of SGLT2 inhibitors in patients with diabetes mellitus and heart failure. Curr Heart Fail Rep. 2017;14:275\u201383.","journal-title":"Curr Heart Fail Rep."},{"key":"745_CR11","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1080\/17425255.2017.1258401","volume":"13","author":"B Tomlinson","year":"2017","unstructured":"Tomlinson B, Hu M, Zhang Y, Chan P, Liu Z-M. Evaluation of the pharmacokinetics, pharmacodynamics and clinical efficacy of empagliflozin for the treatment of type 2 diabetes. Expert Opin Drug Metab Toxicol. 2017;13:211\u201323.","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"745_CR12","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117\u201328.","journal-title":"N Engl J Med"},{"key":"745_CR13","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644\u201357.","journal-title":"N Engl J Med"},{"key":"745_CR14","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1161\/CIRCULATIONAHA.117.029190","volume":"136","author":"M Kosiborod","year":"2017","unstructured":"Kosiborod M, Cavender MA, Fu AZ, Wilding JP, Khunti K, Holl RW, et al. Lower risk of heart failure and death in patients initiated on sodium\u2013glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL Study (comparative effectiveness of cardiovascular outcomes in new users of sodium\u2013glucose cotransporter-2 inhibitors). Circulation. 2017;136:249\u201359.","journal-title":"Circulation"},{"key":"745_CR15","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s12933-017-0575-x","volume":"16","author":"S Gautam","year":"2017","unstructured":"Gautam S, Agiro A, Barron J, Power T, Weisman H, White J. Heart failure hospitalization risk associated with use of two classes of oral antidiabetic medications: an observational, real-world analysis. Cardiovasc Diabetol. 2017;16:93.","journal-title":"Cardiovasc Diabetol."},{"key":"745_CR16","doi-asserted-by":"crossref","first-page":"1253425","DOI":"10.1155\/2017\/1253425","volume":"2017","author":"D von Lewinski","year":"2017","unstructured":"von Lewinski D, Kolesnik E, Wallner M, Resl M, Sourij H. New antihyperglycemic drugs and heart failure: synopsis of basic and clinical data. Biomed Res Int. 2017;2017:1253425.","journal-title":"Biomed Res Int"},{"key":"745_CR17","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1111\/dom.13217","volume":"20","author":"I Raz","year":"2018","unstructured":"Raz I, Mosenzon O, Bonaca MP, Cahn A, Kato ET, Silverman MG, et al. DECLARE-TIMI 58: participants\u2019 baseline characteristics. Diab Obes Metab. 2018;20:1102\u201310.","journal-title":"Diab Obes Metab"},{"key":"745_CR18","doi-asserted-by":"publisher","first-page":"e018097","DOI":"10.1136\/bmjopen-2017-018097","volume":"7","author":"NA Mordi","year":"2017","unstructured":"Mordi NA, Mordi IR, Singh JS, Baig F, Choy A-M, McCrimmon RJ, et al. Renal and Cardiovascular Effects of Sodium\u2013Glucose cotransporter 2 (SGLT2) inhibition in combination with loop Diuretics in diabetic patients with Chronic Heart Failure (RECEDE-CHF): protocol for a randomised controlled double-blind cross-over trial. BMJ Open. 2017;7:e018097.","journal-title":"BMJ Open"},{"key":"745_CR19","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.jjcc.2016.10.019","volume":"69","author":"A Tanaka","year":"2017","unstructured":"Tanaka A, Node K. Emerging roles of sodium\u2013glucose cotransporter 2 inhibitors in cardiology. J Cardiol. 2017;69:501\u20137.","journal-title":"J Cardiol"},{"key":"745_CR20","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.kint.2015.12.038","volume":"89","author":"H Rajasekeran","year":"2016","unstructured":"Rajasekeran H, Lytvyn Y, Cherney DZI. Sodium\u2013glucose cotransporter 2 inhibition and cardiovascular risk reduction in patients with type 2 diabetes: the emerging role of natriuresis. Kidney Int. 2016;89:524\u20136.","journal-title":"Kidney Int"},{"key":"745_CR21","doi-asserted-by":"publisher","first-page":"717","DOI":"10.2337\/dc16-0041","volume":"39","author":"M Abdul-Ghani","year":"2016","unstructured":"Abdul-Ghani M, Del Prato S, Chilton R, DeFronzo RA. SGLT2 inhibitors and cardiovascular risk: lessons learned from the EMPA-REG OUTCOME study. Diab Care. 2016;39:717\u201325.","journal-title":"Diab Care"},{"key":"745_CR22","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","volume":"134","author":"HJL Heerspink","year":"2016","unstructured":"Heerspink HJL, Perkins BA, Fitchett DH, Husain M, Cherney DZI. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation. 2016;134:752\u201372.","journal-title":"Circulation"},{"key":"745_CR23","doi-asserted-by":"publisher","first-page":"3192","DOI":"10.1093\/eurheartj\/ehw110","volume":"37","author":"N Marx","year":"2016","unstructured":"Marx N, McGuire DK. Sodium\u2013glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus. Eur Heart J. 2016;37:3192\u2013200.","journal-title":"Eur Heart J"},{"issue":"262\u2013275","key":"745_CR24","first-page":"e9","volume":"8","author":"WL Baker","year":"2014","unstructured":"Baker WL, Smyth LR, Riche DM, Bourret EM, Chamberlin KW, White WB. Effects of sodium\u2013glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. J Am Soc Hypertens JASH. 2014;8(262\u2013275):e9.","journal-title":"J Am Soc Hypertens JASH."},{"key":"745_CR25","doi-asserted-by":"publisher","first-page":"e004007","DOI":"10.1161\/JAHA.116.004007","volume":"6","author":"M Mazidi","year":"2017","unstructured":"Mazidi M, Rezaie P, Gao H-K, Kengne AP. Effect of sodium\u2013glucose cotransport-2 inhibitors on blood pressure in people with type 2 diabetes mellitus: a systematic review and meta-analysis of 43 randomized control trials with 22 528 patients. J Am Heart Assoc. 2017;6:e004007.","journal-title":"J Am Heart Assoc."},{"key":"745_CR26","doi-asserted-by":"publisher","first-page":"e005686","DOI":"10.1161\/JAHA.117.005686","volume":"6","author":"WL Baker","year":"2017","unstructured":"Baker WL, Buckley LF, Kelly MS, Bucheit JD, Parod ED, Brown R, et al. Effects of sodium\u2013glucose cotransporter 2 inhibitors on 24-hour ambulatory blood pressure: a systematic review and meta-analysis. J Am Heart Assoc. 2017;6:e005686.","journal-title":"J Am Heart Assoc."},{"key":"745_CR27","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1111\/dom.12127","volume":"15","author":"HJ Lambers Heerspink","year":"2013","unstructured":"Lambers Heerspink HJ, de Zeeuw D, Wie L, Leslie B, List J. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diab Obes Metab. 2013;15:853\u201362.","journal-title":"Diab Obes Metab"},{"key":"745_CR28","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1111\/dom.12572","volume":"17","author":"R Chilton","year":"2015","unstructured":"Chilton R, Tikkanen I, Cannon CP, Crowe S, Woerle HJ, Broedl UC, et al. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. Diab Obes Metab. 2015;17:1180\u201393.","journal-title":"Diab Obes Metab"},{"key":"745_CR29","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/1475-2840-13-28","volume":"13","author":"DZ Cherney","year":"2014","unstructured":"Cherney DZ, Perkins BA, Soleymanlou N, Har R, Fagan N, Johansen OE, et al. The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovasc Diabetol. 2014;13:28.","journal-title":"Cardiovasc Diabetol."},{"key":"745_CR30","doi-asserted-by":"publisher","first-page":"F194","DOI":"10.1152\/ajprenal.00520.2013","volume":"306","author":"V Vallon","year":"2014","unstructured":"Vallon V, Gerasimova M, Rose MA, Masuda T, Satriano J, Mayoux E, et al. SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice. Am J Physiol Renal Physiol. 2014;306:F194\u2013204.","journal-title":"Am J Physiol Renal Physiol"},{"key":"745_CR31","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1007\/s00125-016-4008-2","volume":"59","author":"D Cherney","year":"2016","unstructured":"Cherney D, Lund SS, Perkins BA, Groop P-H, Cooper ME, Kaspers S, et al. The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes. Diabetologia. 2016;59:1860\u201370.","journal-title":"Diabetologia"},{"key":"745_CR32","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","volume":"129","author":"DZI Cherney","year":"2014","unstructured":"Cherney DZI, Perkins BA, Soleymanlou N, Maione M, Lai V, Lee A, et al. Renal hemodynamic effect of sodium\u2013glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation. 2014;129:587\u201397.","journal-title":"Circulation"},{"key":"745_CR33","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1172\/JCI72227","volume":"124","author":"E Ferrannini","year":"2014","unstructured":"Ferrannini E, Muscelli E, Frascerra S, Baldi S, Mari A, Heise T, et al. Metabolic response to sodium\u2013glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest. 2014;124:499\u2013508.","journal-title":"J Clin Invest."},{"key":"745_CR34","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1172\/JCI70704","volume":"124","author":"A Merovci","year":"2014","unstructured":"Merovci A, Solis-Herrera C, Daniele G, Eldor R, Fiorentino TV, Tripathy D, et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest. 2014;124:509\u201314.","journal-title":"J Clin Invest."},{"key":"745_CR35","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/nm.3828","volume":"21","author":"C Bonner","year":"2015","unstructured":"Bonner C, Kerr-Conte J, Gmyr V, Queniat G, Moerman E, Th\u00e9venet J, et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med. 2015;21:512\u20137.","journal-title":"Nat Med"},{"key":"745_CR36","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1002\/dmr.5610030204","volume":"3","author":"RA DeFronzo","year":"1987","unstructured":"DeFronzo RA, Ferrannini E. Regulation of hepatic glucose metabolism in humans. Diab Metab Rev. 1987;3:415\u201359.","journal-title":"Diab Metab Rev"},{"key":"745_CR37","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1053\/meta.2002.34700","volume":"51","author":"M Matsuda","year":"2002","unstructured":"Matsuda M, Defronzo RA, Glass L, Consoli A, Giordano M, Bressler P, et al. Glucagon dose-response curve for hepatic glucose production and glucose disposal in type 2 diabetic patients and normal individuals. Metabolism. 2002;51:1111\u20139.","journal-title":"Metabolism."},{"key":"745_CR38","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1172\/JCI108212","volume":"56","author":"DS Schade","year":"1975","unstructured":"Schade DS, Eaton RP. Glucagon regulation of plasma ketone body concentration in human diabetes. J Clin Invest. 1975;56:1340\u20134.","journal-title":"J Clin Invest."},{"key":"745_CR39","doi-asserted-by":"publisher","first-page":"387","DOI":"10.2337\/diab.32.5.387","volume":"32","author":"U Keller","year":"1983","unstructured":"Keller U, Schnell H, Sonnenberg GE, Gerber PP, Stauffacher W. Role of glucagon in enhancing ketone body production in ketotic diabetic man. Diabetes. 1983;32:387\u201391.","journal-title":"Diabetes"},{"key":"745_CR40","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/345158a0","volume":"345","author":"PF M\u00e9ry","year":"1990","unstructured":"M\u00e9ry PF, Brechler V, Pavoine C, Pecker F, Fischmeister R. Glucagon stimulates the cardiac Ca2+ current by activation of adenylyl cyclase and inhibition of phosphodiesterase. Nature. 1990;345:158\u201361.","journal-title":"Nature"},{"key":"745_CR41","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.molmet.2014.11.005","volume":"4","author":"S Ali","year":"2015","unstructured":"Ali S, Ussher JR, Baggio LL, Kabir MG, Charron MJ, Ilkayeva O, et al. Cardiomyocyte glucagon receptor signaling modulates outcomes in mice with experimental myocardial infarction. Mol Metab. 2015;4:132\u201343.","journal-title":"Mol Metab."},{"key":"745_CR42","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.2337\/db15-1356","volume":"65","author":"E Ferrannini","year":"2016","unstructured":"Ferrannini E, Baldi S, Frascerra S, Astiarraga B, Heise T, Bizzotto R, et al. Shift to fatty substrate utilization in response to sodium\u2013glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes. Diabetes. 2016;65:1190\u20135.","journal-title":"Diabetes"},{"key":"745_CR43","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1038\/oby.2012.59","volume":"20","author":"JJ Devenny","year":"2012","unstructured":"Devenny JJ, Godonis HE, Harvey SJ, Rooney S, Cullen MJ, Pelleymounter MA. Weight loss induced by chronic dapagliflozin treatment is attenuated by compensatory hyperphagia in diet-induced obese (DIO) rats. Obes Silver Spring Md. 2012;20:1645\u201352.","journal-title":"Obes Silver Spring Md."},{"key":"745_CR44","doi-asserted-by":"publisher","first-page":"e125","DOI":"10.1038\/nutd.2014.20","volume":"4","author":"M Suzuki","year":"2014","unstructured":"Suzuki M, Takeda M, Kito A, Fukazawa M, Yata T, Yamamoto M, et al. Tofogliflozin, a sodium\/glucose cotransporter 2 inhibitor, attenuates body weight gain and fat accumulation in diabetic and obese animal models. Nutr Diab. 2014;4:e125.","journal-title":"Nutr Diab"},{"key":"745_CR45","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.plefa.2003.11.001","volume":"70","author":"T Fukao","year":"2004","unstructured":"Fukao T, Lopaschuk GD, Mitchell GA. Pathways and control of ketone body metabolism: on the fringe of lipid biochemistry. Prostaglandins Leukot Essent Fatty Acids. 2004;70:243\u201351.","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"745_CR46","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1210\/jc.2015-1884","volume":"100","author":"SI Taylor","year":"2015","unstructured":"Taylor SI, Blau JE, Rother KI. SGLT2 inhibitors may predispose to ketoacidosis. J Clin Endocrinol Metab. 2015;100:2849\u201352.","journal-title":"J Clin Endocrinol Metab"},{"key":"745_CR47","first-page":"533","volume":"38","author":"A Janardhan","year":"2011","unstructured":"Janardhan A, Chen J, Crawford PA. Altered systemic ketone body metabolism in advanced heart failure. Tex Heart Inst J. 2011;38:533\u20138.","journal-title":"Tex Heart Inst J"},{"key":"745_CR48","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1161\/CIRCULATIONAHA.115.017355","volume":"133","author":"G Aubert","year":"2016","unstructured":"Aubert G, Martin OJ, Horton JL, Lai L, Vega RB, Leone TC, et al. The failing heart relies on ketone bodies as a fuel. Circulation. 2016;133:698\u2013705.","journal-title":"Circulation"},{"key":"745_CR49","doi-asserted-by":"publisher","first-page":"567","DOI":"10.33549\/physiolres.932338","volume":"61","author":"M Snorek","year":"2012","unstructured":"Snorek M, Hodyc D, Sediv\u00fd V, Duri\u0161ov\u00e1 J, Skoumalov\u00e1 A, Wilhelm J, et al. Short-term fasting reduces the extent of myocardial infarction and incidence of reperfusion arrhythmias in rats. Physiol Res. 2012;61:567\u201374.","journal-title":"Physiol Res"},{"key":"745_CR50","first-page":"2351","volume":"26","author":"S Srivastava","year":"2012","unstructured":"Srivastava S, Kashiwaya Y, King MT, Baxa U, Tam J, Niu G, et al. Mitochondrial biogenesis and increased uncoupling protein 1 in brown adipose tissue of mice fed a ketone ester diet. FASEB J Off Publ Fed Am Soc Exp Biol. 2012;26:2351\u201362.","journal-title":"FASEB J Off Publ Fed Am Soc Exp Biol."},{"key":"745_CR51","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.2337\/dc16-0330","volume":"39","author":"E Ferrannini","year":"2016","unstructured":"Ferrannini E, Mark M, Mayoux E. CV protection in the EMPA-REG OUTCOME trial: a \u201cThrifty Substrate\u201d hypothesis. Diab Care. 2016;39:1108\u201314.","journal-title":"Diab Care"},{"key":"745_CR52","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1177\/1479164115616901","volume":"13","author":"IJ Neeland","year":"2016","unstructured":"Neeland IJ, McGuire DK, Chilton R, Crowe S, Lund SS, Woerle HJ, et al. Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus. Diab Vasc Dis Res. 2016;13:119\u201326.","journal-title":"Diab Vasc Dis Res."},{"key":"745_CR53","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1210\/jc.2011-2260","volume":"97","author":"J Bolinder","year":"2012","unstructured":"Bolinder J, Ljunggren \u00d6, Kullberg J, Johansson L, Wilding J, Langkilde AM, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012;97:1020\u201331.","journal-title":"J Clin Endocrinol Metab"},{"key":"745_CR54","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ejphar.2014.01.040","volume":"727","author":"M Yokono","year":"2014","unstructured":"Yokono M, Takasu T, Hayashizaki Y, Mitsuoka K, Kihara R, Muramatsu Y, et al. SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats. Eur J Pharmacol. 2014;727:66\u201374.","journal-title":"Eur J Pharmacol"},{"key":"745_CR55","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1002\/jcb.10631","volume":"90","author":"L Zhou","year":"2003","unstructured":"Zhou L, Cryan EV, D\u2019Andrea MR, Belkowski S, Conway BR, Demarest KT. Human cardiomyocytes express high level of Na+\/glucose cotransporter 1 (SGLT1). J Cell Biochem. 2003;90:339\u201346.","journal-title":"J Cell Biochem"},{"key":"745_CR56","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s13300-010-0006-4","volume":"1","author":"J Chen","year":"2010","unstructured":"Chen J, Williams S, Ho S, Loraine H, Hagan D, Whaley JM, et al. Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members. Diab Ther. 2010;1:57\u201392.","journal-title":"Diab Ther."},{"key":"745_CR57","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s12933-016-0473-7","volume":"15","author":"H Kusaka","year":"2016","unstructured":"Kusaka H, Koibuchi N, Hasegawa Y, Ogawa H, Kim-Mitsuyama S. Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome. Cardiovasc Diabetol. 2016;15:157.","journal-title":"Cardiovasc Diabetol."},{"key":"745_CR58","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s12933-014-0148-1","volume":"13","author":"B Lin","year":"2014","unstructured":"Lin B, Koibuchi N, Hasegawa Y, Sueta D, Toyama K, Uekawa K, et al. Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice. Cardiovasc Diabetol. 2014;13:148.","journal-title":"Cardiovasc Diabetol."},{"key":"745_CR59","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12933-016-0489-z","volume":"16","author":"J Habibi","year":"2017","unstructured":"Habibi J, Aroor AR, Sowers JR, Jia G, Hayden MR, Garro M, et al. Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes. Cardiovasc Diabetol. 2017;16:9.","journal-title":"Cardiovasc Diabetol."},{"key":"745_CR60","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s10557-017-6734-1","volume":"31","author":"N Hammoudi","year":"2017","unstructured":"Hammoudi N, Jeong D, Singh R, Farhat A, Komajda M, Mayoux E, et al. Empagliflozin improves left ventricular diastolic dysfunction in a genetic model of type 2 diabetes. Cardiovasc Drugs Ther. 2017;31:233\u201346.","journal-title":"Cardiovasc Drugs Ther"},{"key":"745_CR61","doi-asserted-by":"publisher","first-page":"3328","DOI":"10.1210\/endo.141.9.7673","volume":"141","author":"L Liang","year":"2000","unstructured":"Liang L, Jiang J, Frank SJ. Insulin receptor substrate-1-mediated enhancement of growth hormone-induced mitogen-activated protein kinase activation. Endocrinology. 2000;141:3328\u201336.","journal-title":"Endocrinology"},{"key":"745_CR62","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1159\/000475942","volume":"41","author":"Y Zhou","year":"2017","unstructured":"Zhou Y, Wu W. The sodium\u2013glucose co-transporter 2 inhibitor, empagliflozin, protects against diabetic cardiomyopathy by inhibition of the endoplasmic reticulum stress pathway. Cell Physiol Biochem Int J Exp Cell Physiol Biochem Pharmacol. 2017;41:2503\u201312.","journal-title":"Cell Physiol Biochem Int J Exp Cell Physiol Biochem Pharmacol."},{"key":"745_CR63","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s10557-017-6725-2","volume":"31","author":"Y Ye","year":"2017","unstructured":"Ye Y, Bajaj M, Yang H-C, Perez-Polo JR, Birnbaum Y. SGLT-2 inhibition with dapagliflozin reduces the activation of the Nlrp3\/ASC inflammasome and attenuates the development of diabetic cardiomyopathy in mice with type 2 diabetes. further augmentation of the effects with saxagliptin, a DPP4 inhibitor. Cardiovasc Drugs Ther. 2017;31:119\u201332.","journal-title":"Cardiovasc Drugs Ther"},{"key":"745_CR64","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1530\/JOE-17-0457","volume":"236","author":"P Tanajak","year":"2018","unstructured":"Tanajak P, Sa-Nguanmoo P, Sivasinprasasn S, Thummasorn S, Siri-Angkul N, Chattipakorn SC, et al. Cardioprotection of dapagliflozin and vildagliptin in rats with cardiac ischemia-reperfusion injury. J Endocrinol. 2018;236:69\u201384.","journal-title":"J Endocrinol"},{"key":"745_CR65","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.freeradbiomed.2017.01.035","volume":"104","author":"T-M Lee","year":"2017","unstructured":"Lee T-M, Chang N-C, Lin S-Z. Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts. Free Radic Biol Med. 2017;104:298\u2013310.","journal-title":"Free Radic Biol Med."},{"key":"745_CR66","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s11010-017-3018-9","volume":"433","author":"X Shi","year":"2017","unstructured":"Shi X, Verma S, Yun J, Brand-Arzamendi K, Singh KK, Liu X, et al. Effect of empagliflozin on cardiac biomarkers in a zebrafish model of heart failure: clues to the EMPA-REG OUTCOME trial? Mol Cell Biochem. 2017;433:97\u2013102.","journal-title":"Mol Cell Biochem"},{"key":"745_CR67","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1089\/adt.2013.548","volume":"11","author":"C-C Huang","year":"2013","unstructured":"Huang C-C, Monte A, Cook JM, Kabir MS, Peterson KP. Zebrafish heart failure models for the evaluation of chemical probes and drugs. Assay Drug Dev Technol. 2013;11:561\u201372.","journal-title":"Assay Drug Dev Technol"},{"key":"745_CR68","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.jacc.2017.06.016","volume":"70","author":"JL Januzzi","year":"2017","unstructured":"Januzzi JL, Butler J, Jarolim P, Sattar N, Vijapurkar U, Desai M, et al. Effects of canagliflozin on cardiovascular biomarkers in older adults with type 2\u00a0diabetes. J Am Coll Cardiol. 2017;70:704\u201312.","journal-title":"J Am Coll Cardiol"},{"key":"745_CR69","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.2337\/db16-0733","volume":"66","author":"M Joubert","year":"2017","unstructured":"Joubert M, Jagu B, Montaigne D, Marechal X, Tesse A, Ayer A, et al. The sodium\u2013glucose cotransporter 2 inhibitor dapagliflozin prevents cardiomyopathy in a diabetic lipodystrophic mouse model. Diabetes. 2017;66:1030\u201340.","journal-title":"Diabetes"},{"key":"745_CR70","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1111\/dme.13424","volume":"34","author":"T Sato","year":"2017","unstructured":"Sato T, Miki T, Ohnishi H, Yamashita T, Takada A, Yano T, et al. Effect of sodium\u2013glucose co-transporter-2 inhibitors on impaired ventricular repolarization in people with Type 2 diabetes. Diab Med J Br Diab Assoc. 2017;34:1367\u201371.","journal-title":"Diab Med J Br Diab Assoc."},{"key":"745_CR71","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1097\/MOL.0b013e32830f47cd","volume":"19","author":"J Nilsson","year":"2008","unstructured":"Nilsson J, Bengtsson E, Fredrikson GN, Bj\u00f6rkbacka H. Inflammation and immunity in diabetic vascular complications. Curr Opin Lipidol. 2008;19:519\u201324.","journal-title":"Curr Opin Lipidol"},{"key":"745_CR72","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.it.2011.05.004","volume":"32","author":"D De Nardo","year":"2011","unstructured":"De Nardo D, Latz E. NLRP3 inflammasomes link inflammation and metabolic disease. Trends Immunol. 2011;32:373\u20139.","journal-title":"Trends Immunol"},{"key":"745_CR73","doi-asserted-by":"publisher","first-page":"22","DOI":"10.2337\/db12-1115","volume":"62","author":"VD Dixit","year":"2013","unstructured":"Dixit VD. Nlrp3 inflammasome activation in type 2 diabetes: is it clinically relevant? Diabetes. 2013;62:22\u20134.","journal-title":"Diabetes"},{"key":"745_CR74","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/nri978","volume":"3","author":"S Gordon","year":"2003","unstructured":"Gordon S. Alternative activation of macrophages. Nat Rev Immunol. 2003;3:23\u201335.","journal-title":"Nat Rev Immunol"},{"key":"745_CR75","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1038\/ni.1935","volume":"11","author":"SL Masters","year":"2010","unstructured":"Masters SL, Dunne A, Subramanian SL, Hull RL, Tannahill GM, Sharp FA, et al. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1\u03b2 in type 2 diabetes. Nat Immunol. 2010;11:897\u2013904.","journal-title":"Nat Immunol"},{"key":"745_CR76","doi-asserted-by":"publisher","first-page":"194","DOI":"10.2337\/db12-0420","volume":"62","author":"H-M Lee","year":"2013","unstructured":"Lee H-M, Kim J-J, Kim HJ, Shong M, Ku BJ, Jo E-K. Upregulated NLRP3 inflammasome activation in patients with type 2 diabetes. Diabetes. 2013;62:194\u2013204.","journal-title":"Diabetes"},{"key":"745_CR77","doi-asserted-by":"publisher","first-page":"847827","DOI":"10.1155\/2014\/847827","volume":"2014","author":"J Fuentes-Antr\u00e1s","year":"2014","unstructured":"Fuentes-Antr\u00e1s J, Ioan AM, Tu\u00f1\u00f3n J, Egido J, Lorenzo O. Activation of toll-like receptors and inflammasome complexes in the diabetic cardiomyopathy-associated inflammation. Int J Endocrinol. 2014;2014:847827.","journal-title":"Int J Endocrinol."},{"key":"745_CR78","doi-asserted-by":"publisher","first-page":"e104771","DOI":"10.1371\/journal.pone.0104771","volume":"9","author":"B Luo","year":"2014","unstructured":"Luo B, Li B, Wang W, Liu X, Xia Y, Zhang C, et al. NLRP3 gene silencing ameliorates diabetic cardiomyopathy in a type 2 diabetes rat model. PLoS ONE. 2014;9:e104771.","journal-title":"PLoS ONE"},{"key":"745_CR79","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s10557-013-6501-x","volume":"28","author":"LP Singh","year":"2014","unstructured":"Singh LP. The NLRP3 inflammasome and diabetic cardiomyopathy: editorial to: \u201cRosuvastatin alleviates diabetic cardiomyopathy by inhibiting NLRP3 inflammasome and MAPK pathways in a type 2 diabetes rat model\u201d by Beibei Luo et al. Cardiovasc Drugs Ther. 2014;28:5\u20136.","journal-title":"Cardiovasc Drugs Ther"},{"key":"745_CR80","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1161\/01.RES.86.5.494","volume":"86","author":"KK Griendling","year":"2000","unstructured":"Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res. 2000;86:494\u2013501.","journal-title":"Circ Res"},{"issue":"49","key":"745_CR81","first-page":"241","volume":"2007","author":"E Takimoto","year":"1979","unstructured":"Takimoto E, Kass DA. Role of oxidative stress in cardiac hypertrophy and remodeling. Hypertens Dallas Tex. 1979;2007(49):241\u20138.","journal-title":"Hypertens Dallas Tex"},{"key":"745_CR82","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1097\/01.hjh.0000244956.47114.c1","volume":"24","author":"E Yamamoto","year":"2006","unstructured":"Yamamoto E, Lai Z-F, Yamashita T, Tanaka T, Kataoka K, Tokutomi Y, et al. Enhancement of cardiac oxidative stress by tachycardia and its critical role in cardiac hypertrophy and fibrosis. J Hypertens. 2006;24:2057\u201369.","journal-title":"J Hypertens"},{"key":"745_CR83","doi-asserted-by":"publisher","first-page":"e112394","DOI":"10.1371\/journal.pone.0112394","volume":"9","author":"M Oelze","year":"2014","unstructured":"Oelze M, Kr\u00f6ller-Sch\u00f6n S, Welschof P, Jansen T, Hausding M, Mikhed Y, et al. The sodium\u2013glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity. PLoS ONE. 2014;9:e112394.","journal-title":"PLoS ONE"},{"key":"745_CR84","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.freeradbiomed.2013.05.043","volume":"63","author":"T Wang","year":"2013","unstructured":"Wang T, Mao X, Li H, Qiao S, Xu A, Wang J, et al. N-Acetylcysteine and allopurinol up-regulated the Jak\/STAT3 and PI3K\/Akt pathways via adiponectin and attenuated myocardial postischemic injury in diabetes. Free Radic Biol Med. 2013;63:291\u2013303.","journal-title":"Free Radic Biol Med."},{"key":"745_CR85","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1124\/jpet.112.200808","volume":"345","author":"A Jadhav","year":"2013","unstructured":"Jadhav A, Tiwari S, Lee P, Ndisang JF. The heme oxygenase system selectively enhances the anti-inflammatory macrophage-M2 phenotype, reduces pericardial adiposity, and ameliorated cardiac injury in diabetic cardiomyopathy in Zucker diabetic fatty rats. J Pharmacol Exp Ther. 2013;345:239\u201349.","journal-title":"J Pharmacol Exp Ther"},{"key":"745_CR86","doi-asserted-by":"publisher","first-page":"9583268","DOI":"10.1155\/2016\/9583268","volume":"2016","author":"P Xia","year":"2016","unstructured":"Xia P, Liu Y, Cheng Z. Signaling pathways in cardiac myocyte apoptosis. Biomed Res Int. 2016;2016:9583268.","journal-title":"Biomed Res Int"},{"key":"745_CR87","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1016\/j.ijcard.2013.01.163","volume":"167","author":"G Takemura","year":"2013","unstructured":"Takemura G, Kanoh M, Minatoguchi S, Fujiwara H. Cardiomyocyte apoptosis in the failing heart\u2014a critical review from definition and classification of cell death. Int J Cardiol. 2013;167:2373\u201386.","journal-title":"Int J Cardiol"},{"key":"745_CR88","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/j.1582-4934.2006.tb00291.x","volume":"10","author":"G Takemura","year":"2006","unstructured":"Takemura G, Fujiwara H. Morphological aspects of apoptosis in heart diseases. J Cell Mol Med. 2006;10:56\u201375.","journal-title":"J Cell Mol Med"},{"key":"745_CR89","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/1475-2840-12-158","volume":"12","author":"Z-W Liu","year":"2013","unstructured":"Liu Z-W, Zhu H-T, Chen K-L, Dong X, Wei J, Qiu C, et al. Protein kinase RNA-like endoplasmic reticulum kinase (PERK) signaling pathway plays a major role in reactive oxygen species (ROS)-mediated endoplasmic reticulum stress-induced apoptosis in diabetic cardiomyopathy. Cardiovasc Diabetol. 2013;12:158.","journal-title":"Cardiovasc Diabetol."},{"key":"745_CR90","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1038\/sj.embor.7400779","volume":"7","author":"E Szegezdi","year":"2006","unstructured":"Szegezdi E, Logue SE, Gorman AM, Samali A. Mediators of endoplasmic reticulum stress-induced apoptosis. EMBO Rep. 2006;7:880\u20135.","journal-title":"EMBO Rep"},{"key":"745_CR91","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.3892\/mmr.2014.1956","volume":"9","author":"Y Ji","year":"2014","unstructured":"Ji Y, Zhao Z, Cai T, Yang P, Cheng M. Liraglutide alleviates diabetic cardiomyopathy by blocking CHOP-triggered apoptosis via the inhibition of the IRE-\u03b1 pathway. Mol Med Rep. 2014;9:1254\u20138.","journal-title":"Mol Med Rep."},{"key":"745_CR92","first-page":"496","volume":"42","author":"T Wu","year":"2011","unstructured":"Wu T, Dong Z, Geng J, Sun Y, Liu G, Kang W, et al. Valsartan protects against ER stress-induced myocardial apoptosis via CHOP\/Puma signaling pathway in streptozotocin-induced diabetic rats. Eur J Pharm Sci Off J Eur Fed Pharm Sci. 2011;42:496\u2013502.","journal-title":"Eur J Pharm Sci Off J Eur Fed Pharm Sci."},{"key":"745_CR93","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/S0092-8674(01)00611-0","volume":"107","author":"H Yoshida","year":"2001","unstructured":"Yoshida H, Matsui T, Yamamoto A, Okada T, Mori K. XBP1 mRNA is induced by ATF6 and spliced by IRE1 in response to ER stress to produce a highly active transcription factor. Cell. 2001;107:881\u201391.","journal-title":"Cell"},{"key":"745_CR94","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.ceb.2006.06.005","volume":"18","author":"L Zhao","year":"2006","unstructured":"Zhao L, Ackerman SL. Endoplasmic reticulum stress in health and disease. Curr Opin Cell Biol. 2006;18:444\u201352.","journal-title":"Curr Opin Cell Biol"},{"key":"745_CR95","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.ejphar.2016.02.042","volume":"776","author":"Q Tong","year":"2016","unstructured":"Tong Q, Wu L, Jiang T, Ou Z, Zhang Y, Zhu D. Inhibition of endoplasmic reticulum stress-activated IRE1\u03b1-TRAF2-caspase-12 apoptotic pathway is involved in the neuroprotective effects of telmisartan in the rotenone rat model of Parkinson\u2019s disease. Eur J Pharmacol. 2016;776:106\u201315.","journal-title":"Eur J Pharmacol"},{"key":"745_CR96","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1681\/ASN.2004090768","volume":"16","author":"H Liu","year":"2005","unstructured":"Liu H, Baliga R. Endoplasmic reticulum stress-associated caspase 12 mediates cisplatin-induced LLC-PK1 cell apoptosis. J Am Soc Nephrol JASN. 2005;16:1985\u201392.","journal-title":"J Am Soc Nephrol JASN."},{"key":"745_CR97","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1159\/000329970","volume":"27","author":"FR Sari","year":"2011","unstructured":"Sari FR, Widyantoro B, Thandavarayan RA, Harima M, Lakshmanan AP, Zhang S, et al. Attenuation of CHOP-mediated myocardial apoptosis in pressure-overloaded dominant negative p38\u03b1 mitogen-activated protein kinase mice. Cell Physiol Biochem Int J Exp Cell Physiol Biochem Pharmacol. 2011;27:487\u201396.","journal-title":"Cell Physiol Biochem Int J Exp Cell Physiol Biochem Pharmacol."},{"key":"745_CR98","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1007\/s12011-016-0668-5","volume":"173","author":"X-Q Cong","year":"2016","unstructured":"Cong X-Q, Piao M-H, Li Y, Xie L, Liu Y. Bis(maltolato)oxovanadium(IV) (BMOV) attenuates apoptosis in high glucose-treated cardiac cells and diabetic rat hearts by regulating the unfolded protein responses (UPRs). Biol Trace Elem Res. 2016;173:390\u20138.","journal-title":"Biol Trace Elem Res"},{"key":"745_CR99","doi-asserted-by":"publisher","first-page":"586","DOI":"10.2174\/1389450111314050008","volume":"14","author":"S Hern\u00e1ndez-Res\u00e9ndiz","year":"2013","unstructured":"Hern\u00e1ndez-Res\u00e9ndiz S, Buelna-Chontal M, Correa F, Zazueta C. Targeting mitochondria for cardiac protection. Curr Drug Targets. 2013;14:586\u2013600.","journal-title":"Curr Drug Targets"},{"key":"745_CR100","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1089\/ars.2015.6293","volume":"22","author":"CA Galloway","year":"2015","unstructured":"Galloway CA, Yoon Y. Mitochondrial dynamics in diabetic cardiomyopathy. Antioxid Redox Signal. 2015;22:1545\u201362.","journal-title":"Antioxid Redox Signal"},{"key":"745_CR101","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1161\/CIRCULATIONAHA.113.008476","volume":"130","author":"D Montaigne","year":"2014","unstructured":"Montaigne D, Marechal X, Coisne A, Debry N, Modine T, Fayad G, et al. Myocardial contractile dysfunction is associated with impaired mitochondrial function and dynamics in type 2 diabetic but not in obese patients. Circulation. 2014;130:554\u201364.","journal-title":"Circulation"},{"key":"745_CR102","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s12933-016-0474-6","volume":"15","author":"E Lucas","year":"2016","unstructured":"Lucas E, Vila-Bedmar R, Arcones AC, Cruces-Sande M, Cachofeiro V, Mayor F, et al. Obesity-induced cardiac lipid accumulation in adult mice is modulated by G protein-coupled receptor kinase 2 levels. Cardiovasc Diabetol. 2016;15:155.","journal-title":"Cardiovasc Diabetol."},{"key":"745_CR103","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s00246-011-9889-8","volume":"32","author":"JG Duncan","year":"2011","unstructured":"Duncan JG. Peroxisome proliferator activated receptor-alpha (PPAR\u03b1) and PPAR gamma coactivator-1alpha (PGC-1\u03b1) regulation of cardiac metabolism in diabetes. Pediatr Cardiol. 2011;32:323\u20138.","journal-title":"Pediatr Cardiol"},{"key":"745_CR104","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1038\/nrm3013","volume":"11","author":"B Westermann","year":"2010","unstructured":"Westermann B. Mitochondrial fusion and fission in cell life and death. Nat Rev Mol Cell Biol. 2010;11:872\u201384.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"745_CR105","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1126\/science.1219855","volume":"337","author":"RJ Youle","year":"2012","unstructured":"Youle RJ, van der Bliek AM. Mitochondrial fission, fusion, and stress. Science. 2012;337:1062\u20135.","journal-title":"Science"},{"key":"745_CR106","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1161\/CIRCULATIONAHA.109.906610","volume":"121","author":"S-B Ong","year":"2010","unstructured":"Ong S-B, Subrayan S, Lim SY, Yellon DM, Davidson SM, Hausenloy DJ. Inhibiting mitochondrial fission protects the heart against ischemia\/reperfusion injury. Circulation. 2010;121:2012\u201322.","journal-title":"Circulation"},{"key":"745_CR107","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1097\/CCM.0000000000000817","volume":"43","author":"WW Sharp","year":"2015","unstructured":"Sharp WW, Beiser DG, Fang YH, Han M, Piao L, Varughese J, et al. Inhibition of the mitochondrial fission protein dynamin-related protein 1 improves survival in a murine cardiac arrest model. Crit Care Med. 2015;43:e38\u201347.","journal-title":"Crit Care Med"},{"key":"745_CR108","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1002\/cphy.c140069","volume":"5","author":"DC Bartos","year":"2015","unstructured":"Bartos DC, Grandi E, Ripplinger CM. Ion channels in the heart. Compr Physiol. 2015;5:1423\u201364.","journal-title":"Compr Physiol."},{"key":"745_CR109","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1080\/19336950.2015.1076597","volume":"9","author":"BT Priest","year":"2015","unstructured":"Priest BT, McDermott JS. Cardiac ion channels. Channels. 2015;9:352\u20139.","journal-title":"Channels."},{"key":"745_CR110","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/S0008-6363(02)00809-X","volume":"57","author":"A Baartscheer","year":"2003","unstructured":"Baartscheer A, Schumacher CA, van Borren MMGJ, Belterman CNW, Coronel R, Fiolet JWT. Increased Na+\/H+-exchange activity is the cause of increased [Na+]i and underlies disturbed calcium handling in the rabbit pressure and volume overload heart failure model. Cardiovasc Res. 2003;57:1015\u201324.","journal-title":"Cardiovasc Res"},{"key":"745_CR111","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/S0008-6363(02)00735-6","volume":"57","author":"SM Pogwizd","year":"2003","unstructured":"Pogwizd SM, Sipido KR, Verdonck F, Bers DM. Intracellular Na in animal models of hypertrophy and heart failure: contractile function and arrhythmogenesis. Cardiovasc Res. 2003;57:887\u201396.","journal-title":"Cardiovasc Res"},{"key":"745_CR112","doi-asserted-by":"publisher","first-page":"e002183","DOI":"10.1161\/JAHA.115.002183","volume":"4","author":"R Lambert","year":"2015","unstructured":"Lambert R, Srodulski S, Peng X, Margulies KB, Despa F, Despa S. Intracellular Na+ concentration ([Na+]i) is elevated in diabetic hearts due to enhanced Na+-glucose cotransport. J Am Heart Assoc. 2015;4:e002183.","journal-title":"J Am Heart Assoc."},{"key":"745_CR113","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1161\/CIRCRESAHA.115.303062","volume":"115","author":"T Liu","year":"2014","unstructured":"Liu T, Takimoto E, Dimaano VL, DeMazumder D, Kettlewell S, Smith G, et al. Inhibiting mitochondrial Na+\/Ca2+ exchange prevents sudden death in a Guinea pig model of heart failure. Circ Res. 2014;115:44\u201354.","journal-title":"Circ Res"},{"key":"745_CR114","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1038\/bjp.2008.189","volume":"154","author":"A Baartscheer","year":"2008","unstructured":"Baartscheer A, Hardziyenka M, Schumacher CA, Belterman CNW, van Borren MMGJ, Verkerk AO, et al. Chronic inhibition of the Na+\/H+\u2014exchanger causes regression of hypertrophy, heart failure, and ionic and electrophysiological remodelling. Br J Pharmacol. 2008;154:1266\u201375.","journal-title":"Br J Pharmacol"},{"key":"745_CR115","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.cardiores.2004.09.024","volume":"65","author":"A Baartscheer","year":"2005","unstructured":"Baartscheer A, Schumacher CA, van Borren MMGJ, Belterman CNW, Coronel R, Opthof T, et al. Chronic inhibition of Na+\/H+\u2014exchanger attenuates cardiac hypertrophy and prevents cellular remodeling in heart failure. Cardiovasc Res. 2005;65:83\u201392.","journal-title":"Cardiovasc Res"},{"key":"745_CR116","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1007\/s00125-016-4134-x","volume":"60","author":"A Baartscheer","year":"2017","unstructured":"Baartscheer A, Schumacher CA, W\u00fcst RCI, Fiolet JWT, Stienen GJM, Coronel R, et al. Empagliflozin decreases myocardial cytoplasmic Na(+) through inhibition of the cardiac Na(+)\/H(+) exchanger in rats and rabbits. Diabetologia. 2017;60:568\u201373.","journal-title":"Diabetologia"},{"key":"745_CR117","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1161\/CIRCRESAHA.108.175919","volume":"103","author":"T Liu","year":"2008","unstructured":"Liu T, O\u2019Rourke B. Enhancing mitochondrial Ca2+ uptake in myocytes from failing hearts restores energy supply and demand matching. Circ Res. 2008;103:279\u201388.","journal-title":"Circ Res"},{"key":"745_CR118","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/nrcardio.2012.145","volume":"9","author":"C Kho","year":"2012","unstructured":"Kho C, Lee A, Hajjar RJ. Altered sarcoplasmic reticulum calcium cycling\u2013targets for heart failure therapy. Nat Rev Cardiol. 2012;9:717\u201333.","journal-title":"Nat Rev Cardiol."},{"key":"745_CR119","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1038\/ncpcardio1301","volume":"5","author":"Y Kawase","year":"2008","unstructured":"Kawase Y, Hajjar RJ. The cardiac sarcoplasmic\/endoplasmic reticulum calcium ATPase: a potent target for cardiovascular diseases. Nat Clin Pract Cardiovasc Med. 2008;5:554\u201365.","journal-title":"Nat Clin Pract Cardiovasc Med."},{"key":"745_CR120","first-page":"224","volume":"10","author":"SH Park","year":"2018","unstructured":"Park SH, Khemais-Benkhiat S, Idris-Khodja N, Amoura L, Abbas M, Auger C, et al. Upregulation of sodium\u2013glucose cotransporter 2 (SGLT2) expression in cultured senescent endothelial cells and in arterial sites at risk in vivo in rats. Arch Cardiovasc Dis Suppl. 2018;10:224.","journal-title":"Arch Cardiovasc Dis Suppl."},{"key":"745_CR121","doi-asserted-by":"publisher","first-page":"L1027","DOI":"10.1152\/ajplung.00167.2015","volume":"309","author":"Y Han","year":"2015","unstructured":"Han Y, Cho Y-E, Ayon R, Guo R, Youssef KD, Pan M, et al. SGLT inhibitors attenuate NO-dependent vascular relaxation in the pulmonary artery but not in the coronary artery. Am J Physiol Lung Cell Mol Physiol. 2015;309:L1027\u201336.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"745_CR122","doi-asserted-by":"publisher","first-page":"6305735","DOI":"10.1155\/2016\/6305735","volume":"2016","author":"W Leng","year":"2016","unstructured":"Leng W, Ouyang X, Lei X, Wu M, Chen L, Wu Q, et al. The SGLT-2 inhibitor dapagliflozin has a therapeutic effect on atherosclerosis in diabetic ApoE\u2212\/\u2212 mice. Mediators Inflamm. 2016;2016:6305735.","journal-title":"Mediators Inflamm"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-018-0745-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-018-0745-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-018-0745-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,17]],"date-time":"2024-03-17T15:01:31Z","timestamp":1710687691000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-018-0745-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,10]]},"references-count":122,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["745"],"URL":"https:\/\/doi.org\/10.1186\/s12933-018-0745-5","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,10]]},"assertion":[{"value":"25 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"101"}}